Pharmena S.A. (PHR) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.078x

Based on the latest financial reports, Pharmena S.A. (PHR) has a cash flow conversion efficiency ratio of -0.078x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-820.00K ≈ $-225.68K USD) by net assets (zł10.54 Million ≈ $2.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Pharmena S.A. - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Pharmena S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PHR total liabilities for a breakdown of total debt and financial obligations.

Pharmena S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharmena S.A. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ragnar Metals Ltd AU:RAG	-0.028x
Telecom Plus PLC LSE:TEP	0.263x
SiamEast Solutions Public Company Limited BK:SE	-0.026x
Knusford Bhd KLSE:5035	0.011x
Semac Consultants Limited NSE:SEMAC	-0.027x
Connexion Mobility Ltd AU:CXZ	0.113x
Acme Holdings Bhd KLSE:7131	0.088x
Goyal Aluminiums Limited NSE:GOYALALUM	0.038x

Annual Cash Flow Conversion Efficiency for Pharmena S.A. (2008–2024)

The table below shows the annual cash flow conversion efficiency of Pharmena S.A. from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Pharmena S.A. (PHR) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	zł12.42 Million ≈ $3.42 Million	zł-2.53 Million ≈ $-696.57K	-0.204x	-113.71%
2023-12-31	zł22.23 Million ≈ $6.12 Million	zł33.03 Million ≈ $9.09 Million	1.486x	+654.93%
2022-12-31	zł-6.79 Million ≈ $-1.87 Million	zł1.82 Million ≈ $500.62K	-0.268x	-142.53%
2021-12-31	zł-5.12 Million ≈ $-1.41 Million	zł-3.23 Million ≈ $-887.57K	0.630x	-90.23%
2020-12-31	zł-348.00K ≈ $-95.77K	zł-2.24 Million ≈ $-617.31K	6.445x	+344.95%
2019-12-31	zł5.00 Million ≈ $1.37 Million	zł-13.15 Million ≈ $-3.62 Million	-2.631x	-241.00%
2018-12-31	zł1.94 Million ≈ $532.82K	zł3.61 Million ≈ $994.35K	1.866x	+973.60%
2017-12-31	zł3.56 Million ≈ $980.04K	zł619.00K ≈ $170.36K	0.174x	+208.74%
2016-12-31	zł5.94 Million ≈ $1.64 Million	zł-950.00K ≈ $-261.45K	-0.160x	+66.80%
2015-12-31	zł8.67 Million ≈ $2.39 Million	zł-4.17 Million ≈ $-1.15 Million	-0.481x	-9.53%
2014-12-31	zł13.08 Million ≈ $3.60 Million	zł-5.75 Million ≈ $-1.58 Million	-0.440x	-106.82%
2013-12-31	zł18.05 Million ≈ $4.97 Million	zł-3.84 Million ≈ $-1.06 Million	-0.213x	+52.93%
2012-12-31	zł8.98 Million ≈ $2.47 Million	zł-4.05 Million ≈ $-1.12 Million	-0.451x	-1213.85%
2011-12-31	zł16.45 Million ≈ $4.53 Million	zł666.91K ≈ $183.54K	0.041x	+159.65%
2010-12-31	zł15.91 Million ≈ $4.38 Million	zł-1.08 Million ≈ $-297.50K	-0.068x	-512.69%
2009-12-31	zł16.16 Million ≈ $4.45 Million	zł-179.22K ≈ $-49.32K	-0.011x	-437.74%
2008-12-31	zł15.78 Million ≈ $4.34 Million	zł-32.56K ≈ $-8.96K	-0.002x	--

About Pharmena S.A.

WAR:PHR Poland Biotechnology

Market Cap

$10.36 Million

zł37.65 Million PLN

Market Cap Rank

#26946 Global

#288 in Poland

Share Price

zł3.38

Change (1 day)

-0.59%

52-Week Range

zł2.55 - zł4.22

All Time High

zł28.01